Amgen’s Experimental Sjogren’s Drug Meets Late-Stage Trial Goal
Amgen said its experimental Sjogren’s drug met a late-stage trial goal.
Story updates
01:05:54 PM UTC
SquawkNews
Amgen NASDAQ:AMGN said on Wednesday its experimental drug showed sustained reduction in disease activity in a late-stage study of patients with Sjogren's disease, an autoimmune condition.